Form 4: Orthofix CEO Sells Shares for Tax Obligations

Orthofix Medical Inc.'s President & CEO, Massimo Calafiore, sold shares to cover tax withholding obligations related to restricted stock units.

Summary

• Massimo Calafiore, President & CEO and Director of Orthofix Medical Inc. (OFIX), reported two transactions involving the sale of common stock.
• On January 9, 2026, 9,600 shares of common stock were sold at a weighted average price of $15.8235 per share, with prices ranging from $15.57 to $16.15.
• On January 12, 2026, an additional 9,797 shares of common stock were sold at a weighted average price of $15.2138 per share, with prices ranging from $15.02 to $15.75.
• These sales were non-discretionary, executed to satisfy tax withholding obligations in connection with the settlement of restricted stock units, as part of a pre-existing sell-to-cover requirement approved by the Compensation and Talent Development Committee.
• Following these transactions, Massimo Calafiore beneficially owns 217,237 shares of common stock directly.
• This beneficial ownership includes 135,369 previously reported deferred stock units and 2,031 shares acquired under Orthofix's Stock Purchase Plan on October 31, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the share sales were non-discretionary and for tax withholding purposes, a routine event for executives with equity compensation, not indicative of a change in company fundamentals or management's confidence.

Positives

• The share sales were non-discretionary, mandated by a pre-existing sell-to-cover requirement to satisfy tax withholding obligations, rather than a discretionary sale that might signal a lack of confidence in the company's future.

Negatives

• A reduction in the President & CEO's direct beneficial ownership of common stock by a total of 19,397 shares.

Management Comments

• The sale was made without the exercise of any discretion by the reporting person.
• The sale represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors.

Corporate Governance

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the non-discretionary nature of the sale mitigates concerns about management's confidence in the company's future.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

The reported transactions are routine, non-discretionary sales by the CEO to cover tax obligations associated with restricted stock units. Such 'sell-to-cover' events are common and do not typically reflect a change in the executive's outlook on the company's performance or fundamentals. Therefore, this filing does not provide new information that would warrant a change in investment recommendation; a 'hold' stance is maintained.

Keywords

Orthofix, OFIX, Insider Transaction, Form 4, Stock Sale, CEO, Restricted Stock Units, Tax Withholding, Corporate Governance